Brief: Phase 3 Trial Of Adcetris With Modified Chemo Regimen Shows Non-Inferiority With Unprecedented 3-Year Progression Free Survival Of 94.9% Versus Less Tolerable International Standard Of Care In Advanced Classical Hodgkin Lymphoma
20/06/2023 17:15
June 20 (Reuters) - Seagen Inc SGEN.O :
* PHASE 3 TRIAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) WITH
MODIFIED
CHEMO REGIMEN SHOWS NON-INFERIORITY WITH UNPRECEDENTED 3-YEAR
PROGRESSION FREE SURVIVAL OF 94.9% VERSUS LESS TOLERABLE
INTERNATIONAL STANDARD OF CARE IN ADVANCED CLASSICAL HODGKIN
LYMPHOMA
* SEAGEN INC - PHASE 3 TRIAL OF ADCETRIS IN COMBINATION WITH
CHEMOTHERAPY MET ITS CO-PRIMARY ENDPOINTS
Source text for Eikon: ID:nBw8f7zmta
Further company coverage: SGEN.O
(Reuters.Briefs@thomsonreuters.com)